Coronary artery disease coronary artery stenoses
Conditions
Interventions
None listed
Sponsors
Sint Antonius Ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: All potential participants will be derived from the ICORONARY registry, meaning iCORONARY inclusion criteria apply, These can be found in the protocol, paragraph 4 section 2: inclusion criteria. Additional inclusion criteria that apply to participants in this study are: • The subject is between 30 and 80 years of age • The subject is included in the iCORONARY registry by researchers in the St. Antonius Hospital • The subject has no anatomically significant coronary artery disease on index CCTA (CADRADS 0-2)
Exclusion criteria
Exclusion criteria: All potential participants will be derived from the ICORONARY registry, meaning iCORONARY exclusion criteria apply, These can be found in the protocol, paragraph 4 section 3: exclusion criteria. In addition to all iCORONARY-exclusion criteria (as inclusion for iCORONARY registry indicates that none of these exclusion criteria are met) • The subject is suffering from chronic inflammatory diseases or (auto)immune disorders • The subject is suffering from an active malignancies and/or currently receives treatment for a malignancy • The subject is currently receiving oral, systemic or long-term cutaneous steroid therapy, or any other oral or systemic immune-suppressive medications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective of this study is to investigate: • The difference after 1 year with and without cardiovascular risk modification: o in CaRi Heart Score o in Biomarker-levels o in traditional CT-parameters such as calcium score and CAD RADS score | — |
Secondary
| Measure | Time frame |
|---|---|
| this study also addresses the secondary objectives below: • Correlation between CaRi Heart Score, QRISK 3 score, ESC SCORE2 and biomarker levels at baseline and after 1 year • Ability of CaRi Heart score to predict major adverse cardiac events and CAD progression • Added value of biomarker-levels to CaRi Heart score event prediction | — |
Countries
Netherlands
Outcome results
None listed